Scoping Review: Effectiveness of NDO-LID as new biomarker for leprosy diagnosis

Leprosy is a chronic infectious disease that continues to be prevalent in over 120 countries worldwide, with over 200,000 cases of leprosy. The challenge in controlling leprosy cases is early diagnosis and identification of new cases. It is very important to diagnose quickly and precisely to prevent further disability due to nerve damage. This scoping review aims to assess the effectiveness of NDO-LID as a diagnostic test. The search strategy covered three main databases: PubMed, Science Direct, and Google Scholar, focusing on peer-reviewed studies published from 2019 to 2023. PRISMA guidelines were followed during the literature search. The keywords "NDO-LID" and "NDO-LID Leprosy" were used in the search to find relevant studies. The review included three articles out of 370 relevant ones. The review encompassed 1953 participants across three studies. Part of the review reported on 11 diagnostic test assessments. NDO-LID can detect leprosy patients in both MB and PB cases. Although NDO-LID has higher sensitivity and specificity values than its comparators, further studies are needed to test the accuracy of the diagnostic test more comprehensively to provide stronger and more convincing evidence.